Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01586455
Other study ID # NYMC 550
Secondary ID NYMC IRB L-10,73
Status Completed
Phase Phase 1
First received
Last updated
Start date April 2013
Est. completion date September 2022

Study information

Verified date October 2022
Source New York Medical College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date September 2022
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group 0 Years to 55 Years
Eligibility Inclusion Criteria: - < 55 years of age - Life expectancy greater than 3 months - Lansky performance status = 50% (children) or Karnofsky performance status = 70% (adults) or ECOG performance status 0-2 (adults) - DLCO > 50 percent predicted - Left ventricular ejection fraction > 40% estimated - Creatinine clearance or estimated GFR . 60 mL/min/1.73m2 - Serum bilirubin < 1.5x upper limit of normal - Transaminases < 3x upper limit of normal - Absence of uncontrolled infection - HIV negative Exclusion Criteria: - Fanconi Anemia - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities - Uncontrolled infection - Pregnant or breast-feeding females - Received other investigational agents within 30 days prior to the start of the conditioning regimen

Study Design


Related Conditions & MeSH terms

  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Adrenoleukodystrophy
  • Amegakaryocytic Thrombocytopenia
  • Anemia
  • Anemia, Aplastic
  • Anemia, Diamond-Blackfan
  • Batten Disease
  • Diamond-Blackfan Anemia
  • Fucosidosis
  • Gaucher Disease
  • Gaucher's Disease
  • Krabbe's Disease
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Leukodystrophy, Globoid Cell
  • Leukodystrophy, Metachromatic
  • Metachromatic Leukodystrophy
  • Mucopolysaccharidoses
  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis VI
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndromes
  • Neuronal Ceroid-Lipofuscinoses
  • Niemann-Pick Disease
  • Niemann-Pick Disease, Type C
  • Niemann-Pick Diseases
  • Pick Disease of the Brain
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Severe Aplastic Anemia
  • Thrombocytopenia
  • Wolman Disease

Intervention

Drug:
Human Placental Derived Stem Cell
Infusions of thawed HPDSC to be given following UCB infusion.

Locations

Country Name City State
United States Children's Hospital Colorado Denver Colorado
United States University of Utah Salt Lake City Utah
United States New York Medical College Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
New York Medical College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety to evaluate the safety of human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells in patients with malignant and non-malignant diseases. 100 days
Secondary donor chimerism donor chimerism will be assessed at set timepoints 1 year
Secondary engraftment 1 year
Secondary Survival 100 days and 180 days
Secondary Relapse 100 days and 180 days
Secondary Mortality 1 year
See also
  Status Clinical Trial Phase
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT01200355 - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Phase 4
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT02057185 - Occupational Status and Hematological Disease
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Completed NCT03941769 - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Phase 1/Phase 2
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT02262312 - Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome Phase 0
Completed NCT02188290 - Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation N/A
Recruiting NCT02330692 - Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
Completed NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Phase 1